MCID: LPC002
MIFTS: 54

Lip Cancer

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Lip Cancer

MalaCards integrated aliases for Lip Cancer:

Name: Lip Cancer 12 14
Lip Neoplasms 41 69
Malignant Neoplasm of Oral Aspect of Lip, Not Specified Whether Upper or Lower 12
Malignant Neoplasm of External Lip, Not Specified As Upper or Lower 12
Malignant Neoplasm of Vermilion Border of Lip Unspecified 12
Malignant Neoplasm of Lip, Unspecified, Vermilion Border 12
Malignant Neoplasm of Lip, Unspecified, Inner Aspect 12
Malignant Neoplasm of Lip Unspecified, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Inner Aspect Nos 12
Malignant Neoplasm of Lip, Unspecified, External 12
Malignant Neoplasm of Lip, Vermilion Border Nos 12
Malignant Neoplasm of Labial Commissure of Lip 12
Malignant Neoplasm of Lower Lip, Buccal Aspect 12
Malignant Neoplasm of Vermilion Border of Lip 12
Malignant Neoplasm of Lower Lip, Oral Aspect 12
Malignant Neoplasm of Lip, Inner Aspect Nos 12
Malignant Neoplasm of Other Sites of Lip 12
Malignant Neoplasm of Commissure of Lip 12
Malignant Neoplasm of Lip, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Mucosa 12
Malignant Neoplasm of Lip, Unspecified 12
Malignant Tumor of Lower Labial Mucosa 12
Malignant Tumour of Labial Commissure 12
Malignant Tumor of Commissure of Lip 12
Malignant Tumor of Labial Mucosa 12
Malignant Tumor of the Lip 12
Malignant Tumour of Lip 12
Malignant Tumor of Lip 12
Cancer of Lip 69

Classifications:



Summaries for Lip Cancer

MalaCards based summary : Lip Cancer, also known as lip neoplasms, is related to oral squamous cell carcinoma and melanoma, cutaneous malignant 1. An important gene associated with Lip Cancer is SUMO1 (Small Ubiquitin-Like Modifier 1), and among its related pathways/superpathways are Gene Expression and Cytokine Signaling in Immune system. The drugs Heparin and calcium heparin have been mentioned in the context of this disorder. Affiliated tissues include lung, nk cells and lymph node, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Lip Cancer

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to Lip Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 oral squamous cell carcinoma 29.0 CDKN1A MDM2 TP53
2 melanoma, cutaneous malignant 1 29.0 BRAF TP53
3 actinic cheilitis 28.7 CDKN1A MDM2 MSH2 TP53
4 squamous cell carcinoma 28.7 BRAF CDKN1A TP53
5 skin melanoma 28.6 BRAF CDKN1A MDM2 TP53
6 cheilitis 28.2 CDKN1A MDM2 MSH2 SUMO1 TP53
7 lower lip cancer 12.1
8 upper lip cancer 12.0
9 oral cancer 10.7
10 invasive bladder transitional cell carcinoma 10.2 CDKN1A TP53
11 bladder transitional cell papilloma 10.2 CDKN1A TP53
12 atypical follicular adenoma 10.2 CDKN1A TP53
13 suppressor of tumorigenicity 3 10.2 CDKN1A TP53
14 cerebral primitive neuroectodermal tumor 10.2 MSH2 TP53
15 serous cystadenocarcinoma 10.2 CDKN1A TP53
16 intestinal benign neoplasm 10.2 MSH2 TP53
17 ring chromosome 7 10.2 MDM2 TP53
18 sclerosing liposarcoma 10.2 MDM2 TP53
19 anal squamous cell carcinoma 10.1 MDM2 TP53
20 hereditary breast ovarian cancer syndrome 10.1 MSH2 TP53
21 periosteal osteogenic sarcoma 10.1 MDM2 TP53
22 dedifferentiated liposarcoma 10.1 MDM2 TP53
23 cystadenocarcinoma 10.1 CDKN1A TP53
24 gliomatosis cerebri 10.1 MDM2 TP53
25 soft tissue sarcoma 10.1 MDM2 TP53
26 small cell sarcoma 10.1 MDM2 TP53
27 myxosarcoma 10.1 MDM2 TP53
28 tongue cancer 10.1 CDKN1A TP53
29 embryonal sarcoma 10.1 MDM2 TP53
30 cervical adenocarcinoma 10.1 CDKN1A TP53
31 cellular schwannoma 10.1 MDM2 TP53
32 adult medulloblastoma 10.1 MDM2 TP53
33 colorectal adenoma 10.1 MSH2 TP53
34 muscle cancer 10.1 MDM2 TP53
35 grade iii astrocytoma 10.1 MDM2 TP53
36 nodular ganglioneuroblastoma 10.1 CDKN1A MDM2
37 connective tissue cancer 10.1 MDM2 TP53
38 myxoid liposarcoma 10.0 MDM2 TP53
39 female reproductive organ cancer 10.0 MSH2 TP53
40 nevus of ota 10.0 BRAF TP53
41 cerebellar astrocytoma 10.0 BRAF TP53
42 spitz nevus 10.0 BRAF TP53
43 hyperplastic polyposis syndrome 10.0 BRAF TP53
44 histiocytoma 10.0 MDM2 TP53
45 mature teratoma 10.0 BRAF TP53
46 pleomorphic xanthoastrocytoma 10.0 BRAF TP53
47 pleomorphic adenoma 10.0 MDM2 TP53
48 inflammatory myofibroblastic tumor 10.0 MDM2 TP53
49 autosomal genetic disease 9.9 MSH2 TP53
50 ganglioglioma 9.9 BRAF TP53

Graphical network of the top 20 diseases related to Lip Cancer:



Diseases related to Lip Cancer

Symptoms & Phenotypes for Lip Cancer

GenomeRNAi Phenotypes related to Lip Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 MDM2 MSH2 SUMO1 TP53 BRAF CDKN1A

MGI Mouse Phenotypes related to Lip Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 SUMO1 BRAF TP53 CDKN1A MDM2 MSH2
2 digestive/alimentary MP:0005381 9.85 TP53 CDKN1A MDM2 MSH2 BRAF SUMO1
3 craniofacial MP:0005382 9.8 BRAF TP53 CDKN1A MDM2 SUMO1
4 integument MP:0010771 9.72 BRAF TP53 CDKN1A MDM2 MSH2
5 mortality/aging MP:0010768 9.63 SUMO1 BRAF TP53 CDKN1A MDM2 MSH2
6 liver/biliary system MP:0005370 9.56 BRAF TP53 CDKN1A MDM2
7 neoplasm MP:0002006 9.35 TP53 CDKN1A MDM2 MSH2 BRAF
8 renal/urinary system MP:0005367 8.92 BRAF TP53 CDKN1A MDM2

Drugs & Therapeutics for Lip Cancer

Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
2 calcium heparin Phase 3
3 Coagulants Phase 3
4 Tolonium Chloride Phase 3
5 Hemostatics Phase 3
6 Vaccines Phase 3,Phase 2
7 Protein Kinase Inhibitors Phase 3,Phase 1
8
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
9
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
12
Bevacizumab Approved, Investigational Phase 2 216974-75-3
13 Raspberry Approved, Nutraceutical Phase 1, Phase 2
14 Fluorides Phase 1, Phase 2
15 Fluorodeoxyglucose F18 Phase 1, Phase 2
16 Albumin-Bound Paclitaxel Phase 2
17 Antibodies, Monoclonal Phase 2,Phase 1
18 Immunoglobulins Phase 2,Phase 1
19 Antimitotic Agents Phase 2
20 Antibodies Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
22 Radiopharmaceuticals Phase 1, Phase 2
23 Angiogenesis Inhibitors Phase 2
24 Angiogenesis Modulating Agents Phase 2
25
Gemcitabine Approved Phase 1 95058-81-4 60750
26
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
27
Everolimus Approved Phase 1 159351-69-6 6442177
28
Sirolimus Approved, Investigational Phase 1 53123-88-9 46835353 6436030 5284616
29
Trametinib Approved Phase 1 871700-17-3 11707110
30
Palbociclib Approved, Investigational Phase 1 571190-30-2 5330286 11431660 5005498
31
Etoposide Approved Phase 1 33419-42-0 36462
32
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
33
Mesna Approved, Investigational Phase 1 3375-50-6 598
34 Anti-Bacterial Agents Phase 1
35 Pharmaceutical Solutions Phase 1
36 Anti-Infective Agents Phase 1
37 Antifungal Agents Phase 1
38 Immunosuppressive Agents Phase 1
39 Antimetabolites Phase 1
40 Antimetabolites, Antineoplastic Phase 1
41 Antibiotics, Antitubercular Phase 1
42 Antiviral Agents Phase 1
43 Alkylating Agents Phase 1
44 Topoisomerase Inhibitors Phase 1
45 Etoposide phosphate Phase 1
46 Protective Agents Phase 1
47 Antirheumatic Agents Phase 1
48
Ethanol Approved 64-17-5 702
49
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
50
Nicotine Approved 54-11-5 89594 942

Interventional clinical trials:

(show all 48)

# Name Status NCT ID Phase Drugs
1 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
2 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
3 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
4 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
5 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
6 Erlotinib Prevention of Oral Cancer (EPOC) Active, not recruiting NCT00402779 Phase 3 Erlotinib;Placebo
7 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
8 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
9 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
10 Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer Recruiting NCT03224000 Phase 2
11 Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Recruiting NCT03174275 Phase 2 Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin
12 Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies Recruiting NCT03217747 Phase 1, Phase 2 Avelumab;Utomilumab;PF-04518600;Cisplatin
13 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
14 Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
15 Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Not yet recruiting NCT03258008 Phase 2 Utomilumab
16 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma Recruiting NCT03291938 Phase 1 IACS-010759
17 Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
18 Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation Recruiting NCT03065387 Phase 1 Neratinib;Everolimus;Palbociclib;Trametinib
19 Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors Not yet recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide;Mesna
20 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Not yet recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
21 TAK228 With Carbo and Taxol in Advanced Malignancies Not yet recruiting NCT03430882 Phase 1 TAK-228;Paclitaxel;Carboplatin
22 Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn NCT02812056 Phase 1 Alisertib;TAK-228
23 Lenvatinib and Capecitabine in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
24 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
25 PET/CT and Sentinel Node in Oral Cancer Unknown status NCT01136265
26 Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. Unknown status NCT01919580
27 Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Unknown status NCT01919567
28 Validation of DNA Methylation Biomarkers for Oral Cancer Detection Unknown status NCT02648789
29 Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions Unknown status NCT00173316
30 A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Completed NCT00186433
31 Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Completed NCT02048631
32 Validation of DNA Methylation Biomarkers for Oral Cancer Detection Completed NCT01945697
33 Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Completed NCT01424358 Not Applicable
34 Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Completed NCT01351532 Not Applicable
35 Epstein-Barr Detection in Oral Cancer Completed NCT01039272
36 Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers Recruiting NCT03114501
37 Modeling Adherence to Preventive Swallowing Exercises in Head and Neck Cancer Recruiting NCT03010150
38 HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men Recruiting NCT02897427
39 Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers Recruiting NCT00568490
40 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
41 Early Non Invasive Ventilation and Hematological Malignancies Recruiting NCT02464696
42 Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Recruiting NCT02902406
43 Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study Recruiting NCT02866500 Not Applicable
44 Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Recruiting NCT03239834
45 Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care Recruiting NCT01816841 Not Applicable
46 Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck Recruiting NCT01473784 Not Applicable
47 Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer Active, not recruiting NCT01084733
48 Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors Terminated NCT01137162

Search NIH Clinical Center for Lip Cancer

Cochrane evidence based reviews: lip neoplasms

Genetic Tests for Lip Cancer

Anatomical Context for Lip Cancer

MalaCards organs/tissues related to Lip Cancer:

38
Lung, Nk Cells, Lymph Node, Skin, Kidney, Liver, Heart

Publications for Lip Cancer

Articles related to Lip Cancer:

(show top 50) (show all 104)
# Title Authors Year
1
AHNS Series - Do you know your guidelines? Lip cancer. ( 28580768 )
2017
2
Clinicopathological study of lip cancer: a retrospective hospital-based study in Taiwan. ( 28913905 )
2017
3
Stage is a prognostic factor for surgically treated patients with early-stage lip cancer for whom a 'wait and see' policy in terms of neck status has been implemented. ( 28807064 )
2017
4
Intraoral stents in preventing adverse radiotherapeutic effects in lip cancer patients. ( 28883766 )
2017
5
Hydrochlorothiazide use is strongly associated with risk of lip cancer. ( 28480532 )
2017
6
Changes in the Incidence of Skin and Lip Cancer Between 1978 and 2007. ( 28190452 )
2017
7
Lip Cancer: A Clinicopathological Study and Treatment Outcomes in a 25-Year Experience. ( 26917204 )
2016
8
Correlation between cell cycle proteins and hMSH2 in actinic cheilitis and lip cancer. ( 26842232 )
2016
9
Two-Piece Extraoral Prosthetic Rehabilitation to a Perineural Invasion Lip Cancer. ( 27517479 )
2016
10
High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. ( 26830865 )
2016
11
Lip cancer: A 16-year retrospective epidemiological study in Eastern part of Turkey. ( 27812062 )
2016
12
Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. ( 27841120 )
2016
13
Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. ( 27628318 )
2016
14
Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations. ( 26084614 )
2015
15
Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. ( 25753473 )
2015
16
The pattern of lip cancer occurrence over the 1990-2011 period in public hospitals in Madrid, Spain. ( 26256568 )
2015
17
Oral and lip cancer in solid organ transplant patients--a cohort study from a Swedish Transplant Centre. ( 25497104 )
2015
18
Long-term outcome and subjective quality of life after surgical treatment of lower lip cancer. ( 25261402 )
2014
19
Early diagnosis of lip cancer preceded by a persistent actinic lesion in a kidney transplant patient: a case report. ( 24983181 )
2014
20
Facial cutaneous metastases of advanced rectal malignancy masquerading as lip cancer. ( 25370567 )
2014
21
Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. ( 25241153 )
2014
22
Technique for histological control of surgical margins in lip cancer. ( 24611955 )
2014
23
Quantification of the Surgical Margin Shrinkage in Lip Cancer: Determining the Relation Between the Surgical and Histopathologic Margins. ( 25329844 )
2014
24
Pulsed dose rate brachytherapy of lip cancer. ( 24143149 )
2013
25
Wave technique for treatment of lower lip cancer. ( 22440315 )
2012
26
Lip cancer: retrospective analysis of 181 cases. ( 22136191 )
2012
27
High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on 12 consecutive patients and review of the literature. ( 23052164 )
2012
28
Lip cancer: a 10-year retrospective epidemiological study. ( 22493399 )
2012
29
Antihypertensive drugs and lip cancer in non-Hispanic whites. ( 22869299 )
2012
30
High dose-rate versus low dose-rate brachytherapy for lip cancer. ( 22099044 )
2012
31
Sun protection for all: but especially for those receiving certain hypertensive medications: comment on "Antihypertensive drugs and lip cancer in non-Hispanic whites". ( 22869333 )
2012
32
Surgical management of lip cancer. ( 21808457 )
2011
33
Lip cancer in renal transplant patients. ( 21112239 )
2011
34
Lip cancer: incidence, trends, histology and survival: 1970-2006. ( 20163415 )
2010
35
Lip cancer: a 5-year review in a tertiary referral centre. ( 20129833 )
2010
36
Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study. ( 20383781 )
2010
37
Is elective neck dissection in T1-2, N0 patients with lower lip cancer necessary? ( 19325341 )
2009
38
Survival after lip cancer diagnosis. ( 19165039 )
2009
39
Lip cancer in Western Australia, 1982-2006: a 25-year retrospective epidemiological study. ( 19473154 )
2009
40
Immunosuppression and other risk factors for lip cancer after kidney transplantation. ( 19190169 )
2009
41
Surgical treatment of lip cancer: our experience with 106 cases. ( 19304043 )
2009
42
Comparison of time trends in lip cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII. ( 18573854 )
2008
43
Sentinel lymph node biopsy (SLNB) in management of N0 stage T1-T2 lip cancer as a "same day" procedure. ( 17936674 )
2008
44
L-myc polymorphism in head and neck nonmelanoma skin and lower lip cancers. ( 18645122 )
2008
45
Continuous intraarterial infusion chemotherapy for early lip cancer. ( 17207655 )
2007
46
Brachytherapy in lip cancer. ( 16648757 )
2006
47
Effectiveness of brachytherapy in the treatment of lip cancer: a retrospective study at the istanbul university oncology institute. ( 16418146 )
2005
48
Treatment of lower lip cancer: an experience of 48 cases. ( 15617963 )
2005
49
Characterization of mast cell subpopulations in lip cancer. ( 15817069 )
2005
50
Preventing ultraviolet light lip injury: beachgoer awareness about lip cancer risk factors and lip protection behavior. ( 15762210 )
2005

Variations for Lip Cancer

Expression for Lip Cancer

Search GEO for disease gene expression data for Lip Cancer.

Pathways for Lip Cancer

Pathways related to Lip Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 CDKN1A MDM2 MSH2 SUMO1 TP53
2
Show member pathways
13.15 BRAF CDKN1A SUMO1 TP53
3
Show member pathways
12.84 BRAF CDKN1A MDM2 MSH2 TP53
4
Show member pathways
12.79 CDKN1A MDM2 MSH2 TP53
5 12.62 BRAF CDKN1A MDM2 MSH2 TP53
6
Show member pathways
12.55 CDKN1A MDM2 TP53
7
Show member pathways
12.51 CDKN1A MDM2 MSH2 TP53
8
Show member pathways
12.49 BRAF SUMO1 TP53
9
Show member pathways
12.49 CDKN1A MDM2 SUMO1 TP53
10
Show member pathways
12.42 CDKN1A MSH2 TP53
11
Show member pathways
12.42 MDM2 SUMO1 TP53
12
Show member pathways
12.42 BRAF CDKN1A MDM2 TP53
13
Show member pathways
12.41 CDKN1A MDM2 TP53
14 12.36 CDKN1A MDM2 TP53
15 12.36 CDKN1A MDM2 MSH2 TP53
16
Show member pathways
12.35 BRAF MDM2 TP53
17
Show member pathways
12.33 BRAF CDKN1A MDM2 TP53
18
Show member pathways
12.26 CDKN1A MDM2 TP53
19
Show member pathways
12.23 CDKN1A MDM2 TP53
20 12.22 CDKN1A MDM2 TP53
21 12.17 CDKN1A MDM2 TP53
22 12.16 CDKN1A MDM2 TP53
23 12.14 BRAF CDKN1A MDM2 TP53
24
Show member pathways
12.12 CDKN1A MDM2 TP53
25 12.12 CDKN1A MDM2 TP53
26
Show member pathways
12.07 BRAF CDKN1A MDM2 TP53
27 12.05 CDKN1A MDM2 TP53
28 12.03 BRAF CDKN1A MSH2 TP53
29
Show member pathways
11.98 BRAF CDKN1A MDM2
30 11.97 BRAF MDM2 MSH2 TP53
31 11.95 CDKN1A SUMO1 TP53
32 11.94 BRAF CDKN1A TP53
33
Show member pathways
11.94 BRAF CDKN1A MDM2 TP53
34 11.91 CDKN1A MDM2 SUMO1 TP53
35 11.88 CDKN1A MDM2 TP53
36 11.85 CDKN1A MDM2 MSH2 TP53
37 11.83 CDKN1A MDM2 MSH2 TP53
38 11.77 CDKN1A MDM2 SUMO1
39 11.75 CDKN1A MDM2 TP53
40
Show member pathways
11.74 CDKN1A MDM2 TP53
41 11.71 BRAF CDKN1A MDM2 TP53
42 11.7 CDKN1A MDM2 TP53
43 11.65 BRAF CDKN1A MDM2 TP53
44 11.5 MDM2 TP53
45 11.48 CDKN1A MDM2
46
Show member pathways
11.48 MDM2 SUMO1 TP53
47 11.46 MDM2 TP53
48 11.46 MDM2 TP53
49 11.43 CDKN1A TP53
50 11.43 CDKN1A TP53

GO Terms for Lip Cancer

Cellular components related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.26 CDKN1A MDM2 SUMO1 TP53
2 nuclear body GO:0016604 8.92 CDKN1A MDM2 SUMO1 TP53

Biological processes related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.81 MDM2 SUMO1 TP53
2 positive regulation of gene expression GO:0010628 9.8 BRAF MDM2 TP53
3 response to drug GO:0042493 9.78 CDKN1A MDM2 TP53
4 negative regulation of apoptotic process GO:0043066 9.76 BRAF CDKN1A MDM2 TP53
5 cell cycle arrest GO:0007050 9.65 CDKN1A MSH2 TP53
6 Ras protein signal transduction GO:0007265 9.64 CDKN1A TP53
7 cellular response to drug GO:0035690 9.63 BRAF TP53
8 response to UV GO:0009411 9.62 CDKN1A TP53
9 protein kinase B signaling GO:0043491 9.61 CDKN1A MDM2
10 positive regulation of cell cycle GO:0045787 9.6 MDM2 TP53
11 response to organonitrogen compound GO:0010243 9.59 CDKN1A TP53
12 cellular response to ionizing radiation GO:0071479 9.58 CDKN1A TP53
13 response to antibiotic GO:0046677 9.58 MDM2 TP53
14 intrinsic apoptotic signaling pathway GO:0097193 9.57 CDKN1A TP53
15 positive regulation of reactive oxygen species metabolic process GO:2000379 9.56 CDKN1A TP53
16 response to hyperoxia GO:0055093 9.55 CDKN1A TP53
17 positive regulation of protein export from nucleus GO:0046827 9.54 MDM2 TP53
18 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.54 CDKN1A MDM2 TP53
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 CDKN1A TP53
20 determination of adult lifespan GO:0008340 9.51 MSH2 TP53
21 replicative senescence GO:0090399 9.49 CDKN1A TP53
22 response to UV-B GO:0010224 9.43 MSH2 TP53
23 cellular response to heat GO:0034605 9.43 CDKN1A SUMO1 TP53
24 signal transduction by p53 class mediator GO:0072331 9.4 CDKN1A TP53
25 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.33 CDKN1A MSH2 TP53
26 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
27 cellular response to gamma radiation GO:0071480 9.13 CDKN1A MDM2 TP53
28 response to X-ray GO:0010165 8.8 CDKN1A MSH2 TP53

Molecular functions related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.58 CDKN1A MSH2 TP53
2 p53 binding GO:0002039 9.43 MDM2 TP53
3 protein C-terminus binding GO:0008022 9.43 MSH2 SUMO1 TP53
4 damaged DNA binding GO:0003684 9.37 MSH2 TP53
5 disordered domain specific binding GO:0097718 9.32 MDM2 TP53
6 enzyme binding GO:0019899 9.26 MDM2 MSH2 SUMO1 TP53
7 SUMO transferase activity GO:0019789 9.16 MDM2 SUMO1
8 ubiquitin protein ligase binding GO:0031625 8.92 CDKN1A MDM2 SUMO1 TP53

Sources for Lip Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....